- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 62
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 53 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2569–2592
of 10,574
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Traumatic Brain Injury
- Interventions
- Telephone Outcome Assessment, In-Person Outcome Assessment, 3T Magnetic Resonance Imaging (MRI), Blood Draw
- Behavioral · Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 11
- States / cities
- San Francisco, California • Charlestown, Massachusetts • Cincinnati, Ohio + 8 more
- Conditions
- Osteoarthritis
- Interventions
- LY3556050, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 32 more
- Conditions
- Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
- Interventions
- Milrinone, Placebo (5% Dextrose)
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 0 Hours to 168 Hours
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more
- Conditions
- Psoriasis
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,846 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 182
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Gadsden, Alabama + 153 more
- Conditions
- Prostate Cancer
- Interventions
- AAA817, ARPI, Standard of Care
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 940 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 42
- States / cities
- Homewood, Alabama • Tucson, Arizona • Orange, California + 37 more
- Conditions
- Liver Fibroses, Hepatic Steatosis
- Interventions
- MRI
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 17
- States / cities
- San Francisco, California • Fort Myers, Florida • Lakeland, Florida + 14 more
- Conditions
- Sleep Apnea, Obstructive
- Interventions
- Modafinil
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 51 more
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Inspire therapy, No intervention
- Device · Other
- Lead sponsor
- Inspire Medical Systems, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 43 more
- Conditions
- Fibromyalgia
- Interventions
- [S,S]-Reboxetine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 87 more
- Conditions
- Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
- Interventions
- Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 30 Days and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- San Francisco, California • Boston, Massachusetts • Kansas City, Missouri + 6 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 797 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
- Conditions
- Hemophilia A
- Interventions
- BIIB031 (rFVIIIFc), FVIII (PK subgroup only)
- Drug
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- Up to 11 Years · Male only
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 9 more
- Conditions
- Contraception
- Interventions
- 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)
- Drug
- Lead sponsor
- Premier Research
- Other
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Denver, Colorado • Lexington, Kentucky + 11 more
- Conditions
- Obesity, Overweight
- Interventions
- LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 49
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more
- Conditions
- Heart Failure
- Interventions
- probenecid, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Cincinnati, Ohio • Cleveland, Ohio + 2 more
- Conditions
- Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Fibrolamellar Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Childhood Fibrolamellar Carcinoma, Refractory Childhood Malignant Solid Neoplasm, Refractory Fibrolamellar Carcinoma, Refractory Malignant Solid Neoplasm
- Interventions
- Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan
- Biological · Procedure · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more
- Conditions
- Ataxia Telangiectasia, Genetic Syndrome
- Interventions
- EryDex System
- Combination Product
- Lead sponsor
- Quince Therapeutics S.p.A.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
- Conditions
- Urinary Incontinence
- Interventions
- OnabotulinumtoxinA
- Biological
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more
- Conditions
- Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
- Interventions
- Codrituzumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
- Conditions
- Crohn Disease
- Interventions
- MR Imaging
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 11 Years to 25 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Cabozantinib S-malate, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 410
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 275 more
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma
- Interventions
- oncolytic HSV-1716, dexamethasone, therapeutic conventional surgery, laboratory biomarker analysis
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio